Mechanistic and functional differentiation of tapentadol and tramadol |
| |
Authors: | Raffa Robert B Buschmann Helmut Christoph Thomas Eichenbaum Gary Englberger Werner Flores Christopher M Hertrampf Torsten Kögel Babette Schiene Klaus Straßburger Wolfgang Terlinden Rolf Tzschentke Thomas M |
| |
Affiliation: | Temple University School of Pharmacy, Department of Pharmaceutical Sciences, Philadelphia, PA, USA. |
| |
Abstract: | INTRODUCTION: Many opioid analgesics share common structural elements; however, minor differences in structure can result in major differences in pharmacological activity, pharmacokinetic profile, and clinical efficacy and tolerability. Areas covered: This review compares and contrasts the chemistry, pharmacodynamics, pharmacokinetics, and CNS 'functional activity' of tapentadol and tramadol, responsible for their individual clinical utilities. EXPERT OPINION: The distinct properties of tapentadol and tramadol generate different CNS functional activities, making each drug the prototype of different classes of opioid/nonopioid analgesics. Tramadol's analgesia derives from relatively weak μ-opioid receptor (MOR) agonism, plus norepinephrine and serotonin reuptake inhibition, provided collectively by the enantiomers of the parent drug and a metabolite that is a stronger MOR agonist, but has lower CNS penetration. Tapentadol's MOR agonist activity is several-fold greater than tramadol's, with prominent norepinephrine reuptake inhibition and minimal serotonin effect. Accordingly, tramadol is well-suited for pain conditions for which a strong opioid component is not needed-and it has the benefit of a low abuse potential; whereas tapentadol, a schedule-II controlled substance, is well-suited for pain conditions requiring a strong opioid component-and it has the benefit of greater gastrointestinal tolerability compared to classical strong opioids. Both drugs offer distinct and complementary clinical options. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|